PedAM
Pediatric Disease Annotations & Medicines
| Disease | pulmonary hypertension |
| Phenotype | C0020538|hypertension |
| Sentences | 12 |
| PubMedID- 21821999 | Characterization of pulmonary venous hypertension patients with reactive pulmonary hypertension as compared to proportional pulmonary hypertension. |
| PubMedID- 22530100 | Potential contributing factors include portal hypertension with resulting portopulmonary hypertension and/or egg embolism, and a host immune responses that may be systemic and/or locally directed at parasite antigens in the lung. |
| PubMedID- 23319544 | Chronic exposure to cold caused pulmonary arterial hypertension (cold-induced pulmonary hypertension [ciph]) and increased phosphodiesterase-1c (pde-1c) expression in pulmonary arteries (pas) in rats. |
| PubMedID- 20677289 | Pulmonary arterial hypertension (pah) associated with portal hypertension [portopulmonary hypertension (pphtn)] occurs in 2% to 10% of patients with advanced liver disease and carries a very poor prognosis without treatment. |
| PubMedID- 24736644 | [32] although these lesions resemble plexiform lesions typical for pulmonary artery hypertension, patients with pulmonary hypertension due to left heart disease and/or lung disease, which represent the majority of ph patients do not present with plexiform lesions. |
| PubMedID- 23772325 | The patient had a medical history significant for systemic hypertension, 38 pack-years of tobacco usage, pulmonary hypertension, and severe chronic obstructive pulmonary disease. |
| PubMedID- 22533520 | Another possible mechanism explaining our findings may relate to severe systemic hypertension leading to pulmonary hypertension through increased end-diastolic pressure, and the presence of pulmonary hypertension in patients with heart failure has shown to be a strong and independent adverse prognosticator [15]. |
| PubMedID- 22059182 | Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of canadian pulmonary hypertension physicians. |
| PubMedID- 26407098 | Background: pulmonary arterial hypertension (pah) is one of several forms of pulmonary hypertension: a chronic disease of the pulmonary vasculature. |
| PubMedID- 24516598 | Organ system involvement was defined as described previously [18] with some modifications: ild = bibasilar interstitial fibrosis or ground-glass shadow on computed tomogram (ct); pulmonary arterial hypertension (pah) = clinical evidence of pulmonary hypertension and elevated right ventricular systolic pressure (>45 mmhg) documented by echocardiography in the absence of severe pulmonary interstitial fibrosis; esophagus = apparent dysphagia, reflux symptoms, or hypomotility shown by barium radiography; heart = pericarditis, congestive heart failure, or arrhythmias requiring treatment; kidney = malignant hypertension and rapidly progressive renal failure unexplained by certain diseases other than ssc; joint = inflammatory polyarthralgias or arthritis; and muscle = proximal muscle weakness and elevated serum creatine kinase. |
| PubMedID- 20491346 | The mechanism how the portal hypertension leads to the pulmonary hypertension is not clear. |
| PubMedID- 24015332 | [86] further studies will be required to fully understand the contributions of microparticles to pulmonary arterial hypertension (pah), but with pulmonary hypertension being a devastating disease that is difficult to detect prior to patient decline, these studies suggest that microparticles could potentially serve as biomarkers for early detection of the disease and further our understanding of the pathogenesis of pah. |
Page: 1